Objective To evaluate the safety and effectiveness of Yiqi-Yangyin-Huoxue-Lishui combined with Conbercept in the treatment of diabetic macular edema(DME),and to provide more clinical means and ideas for the treatment of DME by the combination of traditional Chinese and Western medicine.Methods A total of 70 DME patients hospitalized in the Department of Ophthalmology,Pingxiang People's Hospital from June 2019 to June 2022 were selected as the research objects.Monocular drug injection was performed in each treatment cycle,only one eye was enrolled in the study.Six patients were followed up,and 64 patients were included in the statistics.They were divided into treatment group (29 cases)and control group(35 cases)according to admission.The treatment group was given intravitreal injection of Compaercept once combined with oral Yiqi-Yangyin-Huoxue-Lishui Chinese medicine set for 3 months.The control group was given intravitreal injection of Compacept once.The best corrected visual acuity (BCVA),central retinal thickness (CRT),traditional Chinese medicine syndrome score and the number of repeated intraocular drug injection were compared between the two groups before treatment and 1,3 and 6 months after treatment.Results The comparison of BCVA,CRT and traditional Chinese medicine syndrome score before and after treatment between the two groups showed statistically significant differences (P<0.05),while the comparison of BCVA,CRT and traditional Chinese medicine syndrome score between the two groups and their interaction before and after treatment showed no statistically significant differences (P>0.05).BCVA,CRT and traditional Chinese medicine syndrome score of the treatment group 1 and 3 months after treatment and the control group 1 month after treatment were higher than those before treatment,and the differences were statistically significant (P<0.05).There was no significant difference in BCVA,CRT and traditional Chinese medicine syndrome scores 3 months after treatment in the control group and 6 months after treatment in the two groups (P>0.05).CRT at 3 months after treatment rebounded compared with 1 month after treatment.Five cases in the treatment group needed to be re-injected with Compaplomb,less than 15 cases in the control group,and the difference was statistically significant (χ2=4.844,P=0.033).Compared with the average changes of BCVA,CRT and traditional Chinese medicine syndrome score before treatment,the improvement of BCVA,CRT and traditional Chinese medicine syndrome score in the treatment group was always better than that in the control group.In addition,no significant safety issues occurred during treatment in either group.Conclusion The efficacy of Yiqi-Yangyin-Huoxue-Lishui combined with Conbercept in the treatment of DME may be better than that of Conbercept alone,which is helpful to improve postoperative BCVA ands delay the recurrence of macular edema.
王 桃;贺小张; 兰 婷; 何 琼; 何建中;赖 伟;邱艳飞; 黄俊武. 益气养阴活血利水法联合康柏西普治疗糖尿病性黄斑水肿的临床研究[J]. 中国当代医药, 2024, 31(14): 78-.
WANG Tao1 HE Xiaozhang1 LAN Ting1 HE Qiong1 HE Jianzhong1 IAI Wei1 QIU Yanfei1 HUANG Junwu2 1.Department of Pediatric Surgery,Pingxiang . Clinical study of Yiqi-Yangyin-Huoxue-Lishui combined with Conbercept in the treatment of diabetic macular edema. 中国当代医药, 2024, 31(14): 78-.
Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group.The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumabinjections:report1:visualacuity[J].Ophthalmology,2014,121(5):1092-1101.
Li F,Zhang L,Wang Y,et al.One-Year Outcome of Conbercept Therapy for Diabetic Macular Edema[J].Curr Eye Res,2018,43(2):218-223.
[14]
Xu Y,Rong A,Xu W,et al.Comparison of 12 -month therapeutic effect of Conbercept and ranibizumab for diabetic macular edema:a real-life clinical practice study[J].BMC Ophthalmol,2017,17(1):158.